Price
$9.76+33.88%Social Signal Score
Analyst Ratings
12 analystsRevenue
$4.05M+63.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carl Hansen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 562
- Beta
- 1.19
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 6.10
Financials
Revenue
$4.05M+63.4%Net Income
$-55.43MEBITDA
$-41.53MFree Cash Flow
$-35.99MEPS (diluted)
$-0.18Shares Outstanding (diluted)
305.56M+102.3%Operating Expenses
$59.84MCash & Debt
$540.10MReturn of Capital
$0.00Revenue by Segment (annual)
$75.13MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.13M | $-146.41M | $-0.49 |
| 2024 | $28.83M | $-162.86M | $-0.55 |
| 2023 | $38.02M | $-146.40M | $-0.51 |
| 2022 | $485.42M | $158.52M | $0.56 |
| 2021 | $375.20M | $153.46M | $0.56 |
| 2020 | $233.16M | $118.92M | $0.45 |
| 2019 | $11.61M | $-2.21M | $-0.01 |
| 2018 | $8.83M | $309.0K | $0.00 |
Valuation
ABCLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+60.00%Social Signal Score
Mentions (10)
- Newszacks.com·13d ago·Positive
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
View source ↗ - Newsbusinesswire.com·19d ago·Neutral
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
View source ↗ - Newsbenzinga.com·41d ago·Neutral
What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
View source ↗ - Newsseekingalpha.com·50d ago·Neutral
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
View source ↗ - Newsbusinesswire.com·54d ago·Neutral
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
View source ↗ - Newsbenzinga.com·56d ago·Negative
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
View source ↗ - Newsmarketbeat.com·57d ago·Neutral
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
View source ↗ - Newsbusinesswire.com·59d ago·Neutral
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.18 per share
Typical surprise +26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.18 vs $-0.16miss
- Mon, May 11$-0.14 vs $-0.22beat
- Tue, Feb 24$-0.03 vs $-0.18beat
- Thu, Nov 6$-0.19 vs $-0.17miss
- Thu, Aug 7$-0.12 vs $-0.17beat
- Thu, May 8$-0.15 vs $-0.17beat
Estimates and results for ABCL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABCL officers and directors.
- Bought
- $23.2m
- Sold
- —
30 trades
0 trades
- Hayden Michael Rbought
- Montalbano John S.bought
- Booth Andrewbought
- Hayden Michael Rbought
- Montalbano John S.bought
- Thermopylae Holdings Ltd.bought
- Booth Andrewbought
- Thermopylae Holdings Ltd.bought
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABCL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.